Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine (DCS), which is thought to help reduce panic symptoms more effectively by interacting with N-methyl-D-aspartate (NMDA) glutamate receptors, facilitating many forms of learning including the extinction of fear. Participants will be randomly assigned (like flipping a coin) to receive either DCS or a placebo in addition to CBT.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hartford Hospital
• Treatments: Cycloserine

Criteria

Inclusion Criteria:

• Principal diagnosis of panic disorder

Exclusion Criteria:

• History of psychotic disorders or bipolar disorder

• Substance dependence

• Pregnant or breastfeeding

• History of a medical condition that may increase the risks of taking the study drug